Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we report an 81‐year‐old female diagnos...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.541 |
| _version_ | 1797666897194385408 |
|---|---|
| author | Jad Sibai RuiQi Chen Ibrahim Al Nabhani Maria Agustina Perusini Hassan Sibai |
| author_facet | Jad Sibai RuiQi Chen Ibrahim Al Nabhani Maria Agustina Perusini Hassan Sibai |
| author_sort | Jad Sibai |
| collection | DOAJ |
| description | Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we report an 81‐year‐old female diagnosed with BPDCN. The patient was treated with Tagraxofusp and underwent a remarkably long remission (>20 months) without stem‐cell transplantation. She, however, experienced blue toe syndrome and left foot gangrene. We postulate that these previously unreported side effects were caused by microembolization. Characterization of the incidence of thrombo‐ and microembolizations in such a context, as well as prophylactic management options, are warranted. |
| first_indexed | 2024-03-11T20:06:16Z |
| format | Article |
| id | doaj.art-3520f0a0fe10432982f2d63cd1f6731f |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-11T20:06:16Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-3520f0a0fe10432982f2d63cd1f6731f2023-10-03T16:50:47ZengWileyeJHaem2688-61462022-11-01341374137610.1002/jha2.541Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case reportJad Sibai0RuiQi Chen1Ibrahim Al Nabhani2Maria Agustina Perusini3Hassan Sibai4Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network Toronto CanadaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network Toronto CanadaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network Toronto CanadaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network Toronto CanadaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network Toronto CanadaAbstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we report an 81‐year‐old female diagnosed with BPDCN. The patient was treated with Tagraxofusp and underwent a remarkably long remission (>20 months) without stem‐cell transplantation. She, however, experienced blue toe syndrome and left foot gangrene. We postulate that these previously unreported side effects were caused by microembolization. Characterization of the incidence of thrombo‐ and microembolizations in such a context, as well as prophylactic management options, are warranted.https://doi.org/10.1002/jha2.541blastic plasmacytoid dendritic cell neoplasmcase reportgangreneTagraxofusp |
| spellingShingle | Jad Sibai RuiQi Chen Ibrahim Al Nabhani Maria Agustina Perusini Hassan Sibai Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report eJHaem blastic plasmacytoid dendritic cell neoplasm case report gangrene Tagraxofusp |
| title | Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report |
| title_full | Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report |
| title_fullStr | Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report |
| title_full_unstemmed | Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report |
| title_short | Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report |
| title_sort | foot gangrene following tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm case report |
| topic | blastic plasmacytoid dendritic cell neoplasm case report gangrene Tagraxofusp |
| url | https://doi.org/10.1002/jha2.541 |
| work_keys_str_mv | AT jadsibai footgangrenefollowingtagraxofusptreatmentforblasticplasmacytoiddendriticcellneoplasmcasereport AT ruiqichen footgangrenefollowingtagraxofusptreatmentforblasticplasmacytoiddendriticcellneoplasmcasereport AT ibrahimalnabhani footgangrenefollowingtagraxofusptreatmentforblasticplasmacytoiddendriticcellneoplasmcasereport AT mariaagustinaperusini footgangrenefollowingtagraxofusptreatmentforblasticplasmacytoiddendriticcellneoplasmcasereport AT hassansibai footgangrenefollowingtagraxofusptreatmentforblasticplasmacytoiddendriticcellneoplasmcasereport |